After a lively Spring Festival, Ruikang and Nandou resumed work one after another on the seventh day of the Chinese New Year.

Chen Changan was also upgraded from General Manager Chen to President Chen, and the Secretariat was upgraded to President Chen as the new year began.

The company has also been upgraded to Nandou Biomedical Group, which has four subsidiaries: Nandou Scientific Research Center, Ruikang Medical, Ruikang Pharmaceutical, and Ruikang Electronics.

Among them, Ruikang Medical is not a wholly owned subsidiary, but a holding subsidiary.

Almost all shares of Nandou Scientific Research Center belong to Chen Changan. Others only have virtual option incentives, which is a virtual stock with only dividend rights and no decision-making power.

As for Ruikang Pharmaceutical and Ruikang Electronics, these are both newly established subsidiaries of Chen Changan. In his plan, Ruikang Pharmaceutical will be responsible for the production of genetic agents in the future and become a subsidiary specializing in the production of pharmaceuticals.

Ruikang Electronics is paving the way for future products. Medical equipment cannot avoid electronics and semiconductors, especially the higher-end equipment, the more powerful hardware support is needed.

So Chen Changan established a Ruikang Electronics, which will first do the preliminary work of talent reserves and training, and build the team first, and will use it sooner or later.

As for the group's board of directors, because Nandou Biomedical Group is Chen Changan's wholly-owned company, there is no need to establish a board of directors at all. However, Yu Cheng still gave Chen Changan the position of executive director.

Generally speaking, executive directors are not responsible for specific business affairs, but are only responsible for convening the board of directors, convening shareholders' meetings, and then deciding on the development direction of the company.

The person who is specifically responsible for company affairs decisions is the president/CEO.

Chen Changan is both the executive director and the president, in order to take care of all the affairs of the group, so that he can manage all the affairs of the group's subsidiaries and the group headquarters. From daily handling work to large-scale matters that need to be held to hold a shareholders' meeting to decide, they must be handled according to his decision.

The original Secretariat was also upgraded to the President's Office, and Guan Kou was promoted, from an administrative secretary to the director of the President's Office of Chen Chang'an, responsible for the entire President's Office.

After the expansion of the President's Office, three new people were also recruited, and the original Shang Ning and Zhang Wenying formed a six-person team, responsible for inspecting, assessing, supervising and coordinating the work progress of various departments, summarizing the work situation of various departments, and also taking into account the processing and summarizing daily documents to help Chen Chang'an share the work.

Simply put, the entire President's Office is a department that revolves around Chen Chang'an, reduces the burden for him, and monitors the entire group.

A man who owns the entire group is so arrogant.

......

After returning to work, the first thing Chen Changan did was to promote everyone. Because Ruikang Medical is still relatively important, Chen Changan still served as the CEO of Ruikang Medical. However, Yu Cheng was promoted to the next level and became the vice president of Ruikang Medical, responsible for Ruikang's daily operational affairs.

Yang Hui from the production center was also promoted to a serious person in charge and enjoyed virtual equity incentives.

At the scientific research center, Bai Bingchun was also promoted to the general manager of the scientific research center, and he was given the daily operation work.

As for the newly established Ruikang Electronics and Ruikang Pharmaceuticals, Chen Changan also found a headhunting company and was looking for reliable executives to lead the company. After all, he doesn't have that much energy to be responsible for everything in the group alone.

Just controlling the group's big and small affairs, he is also responsible for some scientific research from time to time. It is enough for him to be busy with cheating on Wang Jia and Yun Heng.

But his warding was not in vain.

On March 8, just half a month after the Spring Festival, the heads of the two new subsidiaries had not yet found good news, Yunheng's project team first came to the project team.

"Mr. Chen, our cancer gene editing project has edited forty-six cancer genes!"

"Common cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, nasopharyngeal cancer, esophageal cancer, gastric cancer, uterine cancer, ovarian cancer, liver cancer, melanoma and leukemia have all been included in gene editing treatment projects."

"Especially the most common cancers are lung cancer, gastric cancer, liver cancer, and nodule and colorectal cancer. These four cancers together account for more than half of the total cancer incidence rate. There are about 700,000 new cases of lung cancer every year."

"In clinical trials, our gene editing program can completely improve the survival of these cancer patients by more than 2 times. The survival rate of early patients exceeds 90% and the survival rate of 20 years is also estimated to exceed 60%!"

"Now, only about 5% of rare cancers cannot be included in our gene editing treatment methods for various reasons, but the current results are enough to meet the needs of the market!"

Yes, a special targeted drug that can have an effect on 95% of cancer can add a new immune weapon to the human body, providing new hope for survival for cancer patients!

This drug should be launched as soon as possible. Every day, countless cancer patients may die because they have no time to receive treatment!

Chen Changan also understood this truth. After he confirmed that the gene-editing drugs had been fully verified in clinical practice, he licked his face and called Director Kang again.

However, this time the listing approval is not as easy as the cardiomyocyte healing agent.

The drug administration has very strong opinions on gene-edited drugs!

The reason is nothing special. This is a drug that involves modifying human genes. Unlike cardiomyocyte agents, it is just re-editing the cardiomyocytes, and it is not considered modifying the gene.

However, Yun Heng's project this time was a serious drug involving gene editing, which directly injected the human body with an immune gene that was originally not available to the human body. This immune weapon will also destroy the cell's genes. Although it destroys directed cancer cells, this is also a means to change the human genes.

Just imagine, if this immune system gene can be inherited, is it a good or a bad thing for the next generation?

Although it seems like a good thing, after all, it is definitely good that the human body has an immune weapon or an immune weapon to fight cancer. But what will happen if this gene changes again during the inheritance process?

You should know that the human genes themselves have been replicated, mutated, replicated, and mutated countless times, and finally formed the current stable inheritance method. Even so, many diseases are transmitted through inheritance, such as thalassemia.

There are uncertain heritable genetic material in gene editing, which will inevitably mix into the human gene pool. If this human-edited immune gene has any unpredictable changes during the inheritance process, and the immune gene becomes a defective gene or a certain virus, these are all unpredictable consequences!

Even though Yun Heng's experimental data proves that this gene editing technology is indeed very practical for cancer treatment, the hidden risks behind it have to worry the relevant departments.

Moreover, this risk cannot be avoided or guaranteed to not occur!

Even Director Kang cannot stand up to the public and pass the approval of this gene editing agent for the market.
Chapter completed!